Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Regular Articles Endocrinology

Comparison of 111In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy

Marion de Jong, Wout A. P. Breeman, Willem H. Bakker, Peter P. M. Kooij, Bert F. Bernard, Leo J. Hofland, Theo J. Visser, Ananth Srinivasan, Michelle A. Schmidt, Jack L. Erion, Joseph E. Bugaj, Helmut R. Mäcke and Eric P. Krenning
Marion de Jong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wout A. P. Breeman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem H. Bakker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter P. M. Kooij
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bert F. Bernard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo J. Hofland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo J. Visser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananth Srinivasan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle A. Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack L. Erion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph E. Bugaj
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helmut R. Mäcke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric P. Krenning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published February 1998
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

We evaluated the following 111In-labeled somatostatin (SS) analogues (diethylenetriaminepentaacetic acid, DTPA; tetraazacyclododecanetetraacetic acid, DOTA): [DTPA0]octreotide, [DTPA0,Tyr3]octreotide, [DTPA0,d-Tyr1]octreotide, [DTPA0,Tyr3]octreotate [Thr(ol) in octreotide replaced with Thr], and [DOTA0,Tyr3]octreotide, in vitro and in vivo.

In vitro, all compounds showed high and specific binding to SS receptors in mouse pituitary AtT20 tumor cell membranes, and IC50s were in the nanomolar range. Furthermore, all compounds showed specific internalization in rat pancreatic tumor cells; uptake of [111In-DTPA0,Tyr3]octreotate was the highest of the compounds tested, and that of [111In-DTPA0,d-Tyr1]octreotide was the lowest. Biodistribution experiments in rats showed that, 4, 24, and 48 h after injection of [111In-DTPA0,Tyr3]octreotide, [111In-DTPA0,Tyr3]octreotate, and [111In-DOTA0,Tyr3]octreotide, radioactivity in the octreotide-binding, receptor-expressing tissues and tumor-to-blood ratios were significantly higher than those after injection of [111In-DTPA0]octreotide. Uptake of [111In-DTPA0,Tyr3]octreotate in the target organs was also, in vivo, the highest of the radiolabeled peptides tested, whereas that of [111In-DTPA0,d-Tyr1]octreotide was the lowest. Uptake of [111In-DTPA0,Tyr3]octreotide, [111In-DTPA0,Tyr3]octreotate, and [111In-DOTA0,Tyr3]octreotide in target tissues was blocked by >90% by 0.5 mg of unlabeled octreotide, indicating specific binding to the octreotide receptors. Blockade of [111In-DTPA0,d-Tyr1]octreotide was >70%. In conclusion, radiolabeled [DTPA0,Tyr3]octreotide and, especially, [DTPA0,Tyr3]octreotate and their DOTA-coupled counterparts are most promising for scintigraphy and radionuclide therapy of SS receptor-positive tumors in humans.

Footnotes

  • ↵1 This work was supported by Swiss National Science Foundation Grant 31-42516/94 and the “Regionale Krebsliga beider Basel” (both to H. R. M.).

  • ↵2 To whom requests for reprints should be addressed, at Department of Nuclear Medicine, V220, University Hospital Rotterdam, 3015 GD Rotterdam, the Netherlands. Phone: 31 10 4635781; Fax: 31 10 4635997; E-mail: dejong@nuge.azr.nl.

  • Received August 6, 1997.
  • Accepted December 3, 1997.
  • ©1998 American Association for Cancer Research.
PreviousNext
Back to top
February 1998
Volume 58, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of 111In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comparison of 111In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy
Marion de Jong, Wout A. P. Breeman, Willem H. Bakker, Peter P. M. Kooij, Bert F. Bernard, Leo J. Hofland, Theo J. Visser, Ananth Srinivasan, Michelle A. Schmidt, Jack L. Erion, Joseph E. Bugaj, Helmut R. Mäcke and Eric P. Krenning
Cancer Res February 1 1998 (58) (3) 437-441;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of 111In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy
Marion de Jong, Wout A. P. Breeman, Willem H. Bakker, Peter P. M. Kooij, Bert F. Bernard, Leo J. Hofland, Theo J. Visser, Ananth Srinivasan, Michelle A. Schmidt, Jack L. Erion, Joseph E. Bugaj, Helmut R. Mäcke and Eric P. Krenning
Cancer Res February 1 1998 (58) (3) 437-441;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles Endocrinology

  • In Situ Aromatization Enhances Breast Tumor Estradiol Levels and Cellular Proliferation
  • High Affinity Binding and Direct Antiproliferative Effects of LHRH Analogues in Human Ovarian Cancer Cell Lines
Show more Regular Articles Endocrinology

Articles

  • In Situ Aromatization Enhances Breast Tumor Estradiol Levels and Cellular Proliferation
  • High Affinity Binding and Direct Antiproliferative Effects of LHRH Analogues in Human Ovarian Cancer Cell Lines
  • Multiple Roles for the Wilms' Tumor Suppressor, WT1
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement